Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Skin Neoplasms 1Melanoma 1

Interventions

pembrolizumab 8Nivolumab 6Ipilimumab 6cemiplimab 4aldesleukin 3Interleukin-2 3Blood Specimen Collection 3fludarabine 2Specimen Handling 2HhAntag691 2Cyclophosphamide 2Biopsy 2trametinib 1spartalizumab 1sonidegib 1pertuzumab 1lifileucel 1four-arm poly(ethylene oxide)-b-poly(2-(diethylamino)ethyl methacrylate) 1fludarabine phosphate 1dabrafenib 1brodalumab 1atezolizumab 1Vitamin A 1Trastuzumab 1Tissue Banks 1Surgical Procedures, Operative 1Standard of Care 1Second Harmonic Generation Microscopy 1Resistance Training 1Red Light 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Skin Neoplasms × Naltrexone × Clear all
NCT05968690 2025-09-18

Naltrexone and Propranolol Combined With Immunotherapy

Rutgers, The State University of New Jersey

Phase 1 Recruiting
12 enrolled
Dermatologic

Melanoma, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡